LXRX Lexicon Pharmaceuticals, Inc.

15.74
+0.19  (1.22%)
Previous Close 15.55
Open 15.50
Price To book 8.74
Market Cap 1.64B
Shares 104,036,000
Volume 745,880
Short Ratio 16.86
Av. Daily Volume 664,666

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
Sotagliflozin
Type 1 Diabetes
PDUFA date under priority review extended by three months to February 28, 2017.
Telotristat etiprate
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016.
Sotagliflozin
Type 2 Diabetes

Latest News

  1. 3 Stocks We're Watching in the First Quarter
  2. Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference
  3. The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals
  4. 4 FDA Decisions to Watch Out for in Feb 2017
  5. 5 Small-Cap Biotech Stocks to Buy in February
  6. 5 Biotech Stocks You'll Want to Watch in the 1st Quarter
  7. Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
  8. Lexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference
  9. 7 Key FDA Decisions and Catalysts Expected in January and February
  10. Blog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint
  11. Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
  12. Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : December 19, 2016
  13. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : December 16, 2016
  14. Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc. (LXRX) And Neuroderm Ltd (NDRM)
  15. TherapeuticsMD Soars On Positive Menopause Drug Clinical Trial Results
  16. Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF
  17. 10 Major Pharma and FDA Catalysts Coming in December
  18. Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock?
  19. Lexicon Announces the Establishment of the Commercial Leadership Team for Telotristat Ethyl
  20. Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl

SEC Filings

  1. PRE 14A - Other preliminary proxy statements 17614896
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17604834
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17538517
  4. CT ORDER - Confidential treatment order 162060772
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978362
  6. 8-K - Current report 161976678
  7. 8-K - Current report 161963337
  8. 8-K - Current report 161921464
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807451
  10. 8-K - Current report 161805972